Results of RCTs comparing radiotherapy plus chemotherapy to chemotherapy alone
| Trial . | Intervention control participants . | OS, % . | EFS, % . | PFS, % . | Late AE, % . | Median follow-up . | Reference . |
|---|---|---|---|---|---|---|---|
| HD.6 | Arm A: ABVD only (n = 196) | *94 vs 87 at 12 y | 85 vs 80 at 12 y | 87 vs 92 at 12 y | Second cancers: 5.1 vs 11.33 | 11.3 y | 14 |
| Arm B: STNI with or without ABVD (n = 203) | HR for death: 0.50; 95% CI: 0.25-0.99 (P = .04) | HR: 0.88; 95% CI: 0.54-1.43 (P = .60) | HR: 1.91; 95% CI: 0.99-3.69 (P = .05) | Death: 6.1 vs 11.8 |
| Trial . | Intervention control participants . | OS, % . | EFS, % . | PFS, % . | Late AE, % . | Median follow-up . | Reference . |
|---|---|---|---|---|---|---|---|
| HD.6 | Arm A: ABVD only (n = 196) | *94 vs 87 at 12 y | 85 vs 80 at 12 y | 87 vs 92 at 12 y | Second cancers: 5.1 vs 11.33 | 11.3 y | 14 |
| Arm B: STNI with or without ABVD (n = 203) | HR for death: 0.50; 95% CI: 0.25-0.99 (P = .04) | HR: 0.88; 95% CI: 0.54-1.43 (P = .60) | HR: 1.91; 95% CI: 0.99-3.69 (P = .05) | Death: 6.1 vs 11.8 |
ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine; AE, adverse events; CI, confidence interval; EFS, event-free survival; HR, hazard ratio; OS, overall survival; STNI, subtotal nodal irradiation.
Primary outcome.